🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07462091
Recruiting Not applicable

Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection

NCT07462091 · tracked via the Priya Life Science China tracker
Sponsor
Northern Jiangsu People's Hospital
Phase
Not applicable
Started
2026-03-25
Last updated
2026-04-01

Condition(s) studied

CirrhosisHypersplenismHypertension, Portal

Investigational drug(s) / intervention(s)

Vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection

Vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection: The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.

Study summary

This study aimed to evaluate the effectiveness and safety of vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection, and to assess its impact on postoperative digestive complications and quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. A clinical, radiological or histologic diagnosis of cirrhosis of any etiology 2. Splenomegaly with secondary hypersplenism 3. Bleeding portal hypertension 4. No evidence of portal vein system thrombosis by ultrasound evaluation and angio-CT 5. Informed consent to participate in the study Exclusion Criteria: 1. Delayed gastric emptying 2. Diarrhea 3. Hepatocellular carcinoma or any other malignancy, 4. Hypercoagulable state other than the liver disease related 5. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs. 6. Child - Pugh C 7. Recent peptic ulcer disease 8. History of Hemorrhagic stroke 9. Pregnancy. 10. Uncontrolled Hypertension 11. Human immunodeficiency virus (HIV) infection

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Clinical Medical College of Yangzhou University Yangzhou Jiangsu Recruiting
Clinical Medical College, Yangzhou University Yangzhou Jiangsu Completed

More Northern Jiangsu People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07462091 on ClinicalTrials.gov ↗ ← All trials in China